Premier Biomedical has released the results of a completed phase 1 mouse testing of its breast cancer therapy, with results demonstrating the methodology's ability to outperform chemotherapy with a much lower mortality rate, smaller tumor volume, and increased subject weight gain recorded 19 days after first treatment.
Twenty-five days into the study, the mice administered Premier Biomedical's treatment experienced a 100 percent survival rate without encountering a single cancer-related fatality. This is compared to a mortality rate of nearly one-third of the mice subjected to chemotherapy.
In addition, the tumors of the mice given Premier Biomedical's treatment shrunk in size in the days following the application while the size of the tumors within the mice subjected to chemotherapy rapidly grew throughout the duration of the study.
In animal cancer studies, greater weight of the subject typically indicates greater health. Premier Biomedical reports that the mice that received its treatment gained weight over the course of the study and consistently had a greater weight than both the untreated mice and the mice which were subjected to chemotherapy.
"Every doctor has seen a patient whose mortality was undoubtedly certain, yet miraculously fought against all odds and lived. In these mice test results, an unlikely biological process appears to occur in which the immune system is enabled by the treatment and fights off and kills the cancer. It is this process that we believe we are replicating in Premier Biomedical's anti-cancer methodologies," Mitchell S. Felder, M.D. inventor of the core technology, stated in the press release.
William A. Hartman, CEO and president of Premier Biomedical, emphasized the importance of the phase 1 results and noted that while the treatment is in its early stages, it has high potential in the fight against cancer.
"It is an understatement to say that the results produced here are remarkable," Hartman said. "Premier Biomedical's methodology is undoubtedly in its infancy. But with the right funding, support from our organizational partners and from the compassionate cancer community, we have good reason to believe that we can cure breast cancer. Just as significantly, we have good reason to believe that we may be able to finally offer a more effective treatment option that saves patients from the harm of chemotherapy, which remains the best current and available treatment today."
For more information, visit premierbiomedicalinc.com
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net